Clinical Trial Detail

NCT ID NCT01258855
Title Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Aldesleukin

Aflibercept

Age Groups: adult

No variant requirements are available.